Arrow Mark Colorado Holdings LLC Agios Pharmaceuticals, Inc. Transaction History

Arrow Mark Colorado Holdings LLC

$7.03 Billion
Q3 2024

A detailed history of Arrow Mark Colorado Holdings LLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Arrow Mark Colorado Holdings LLC holds 882,731 shares of AGIO stock, worth $29.4 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares

882,731

Previous 1,019,357 13.4%

Holding current value

$29.4 Million

Previous $44 Million 10.77%

% of portfolio

0.56%

Previous 0.58%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$41.19 - $49.72 $5.63 Million - $6.79 Million	-136,626 Reduced 13.4%	882,731 $39.2 Million
Q2 2024 Aug 14, 2024	SELL	$27.55 - $48.83 $13.8 Million - $24.4 Million	-499,806 Reduced 32.9%	1,019,357 $44 Million
Q1 2024 May 15, 2024	SELL	$21.32 - $34.81 $740,209 - $1.21 Million	-34,719 Reduced 2.23%	1,519,163 $44.4 Million
Q4 2023 Feb 14, 2024	SELL	$19.97 - $24.53 $386,858 - $475,195	-19,372 Reduced 1.23%	1,553,882 $34.6 Million
Q2 2023 Aug 14, 2023	BUY	$21.38 - $29.19 $332,437 - $453,875	15,549 Added 1.0%	1,573,254 $44.6 Million
Q1 2023 May 15, 2023	BUY	$21.74 - $30.93 $2.54 Million - $3.61 Million	116,719 Added 8.1%	1,557,705 $35.8 Million
Q4 2022 Feb 14, 2023	BUY	$24.81 - $31.52 $1.5 Million - $1.91 Million	60,597 Added 4.39%	1,440,986 $40.5 Million
Q3 2022 Nov 14, 2022	BUY	$19.51 - $34.14 $50,901 - $89,071	2,609 Added 0.19%	1,380,389 $39 Million
Q2 2022 Aug 15, 2022	BUY	$17.06 - $31.42 $1.4 Million - $2.57 Million	81,832 Added 6.31%	1,377,780 $30.5 Million
Q1 2022 May 16, 2022	SELL	$26.68 - $34.81 $432,642 - $564,478	-16,216 Reduced 1.24%	1,295,948 $37.7 Million
Q4 2021 Feb 14, 2022	BUY	$29.58 - $49.78 $6.86 Million - $11.5 Million	231,855 Added 21.46%	1,312,164 $43.1 Million
Q3 2021 Nov 15, 2021	BUY	$41.92 - $58.18 $1.97 Million - $2.73 Million	46,878 Added 4.54%	1,080,309 $49.9 Million
Q2 2021 Aug 16, 2021	SELL	$52.06 - $61.27 $4.48 Million - $5.28 Million	-86,135 Reduced 7.69%	1,033,431 $57 Million
Q1 2021 May 17, 2021	SELL	$44.23 - $57.5 $2.14 Million - $2.78 Million	-48,369 Reduced 4.14%	1,119,566 $57.8 Million
Q4 2020 Feb 16, 2021	BUY	$33.21 - $46.54 $2.86 Million - $4.01 Million	86,111 Added 7.96%	1,167,935 $50.6 Million
Q3 2020 Nov 16, 2020	BUY	$33.87 - $55.93 $32,853 - $54,252	970 Added 0.09%	1,081,824 $37.9 Million
Q2 2020 Aug 14, 2020	SELL	$34.45 - $53.48 $943,482 - $1.46 Million	-27,387 Reduced 2.47%	1,080,854 $57.8 Million
Q1 2020 May 15, 2020	SELL	$31.52 - $53.81 $5,043 - $8,609	-160 Reduced 0.01%	1,108,241 $39.3 Million
Q4 2019 Feb 14, 2020	BUY	$30.08 - $50.59 $2.09 Million - $3.51 Million	69,326 Added 6.67%	1,108,401 $52.9 Million
Q3 2019 Nov 14, 2019	BUY	$32.4 - $49.58 $7.04 Million - $10.8 Million	217,359 Added 26.45%	1,039,075 $33.7 Million
Q2 2019 Aug 14, 2019	BUY	$46.17 - $68.1 $3.87 Million - $5.71 Million	83,820 Added 11.36%	821,716 $41 Million
Q1 2019 May 15, 2019	BUY	$45.92 - $67.67 $2.58 Million - $3.8 Million	56,093 Added 8.23%	737,896 $49.8 Million
Q4 2018 Feb 14, 2019	BUY	$42.73 - $76.53 $1.42 Million - $2.54 Million	33,147 Added 5.11%	681,803 $31.4 Million
Q3 2018 Nov 14, 2018	BUY	$71.67 - $91.95 $6.77 Million - $8.68 Million	94,392 Added 17.03%	648,656 $50 Million
Q2 2018 Aug 14, 2018	SELL	$73.22 - $99.55 $1.29 Million - $1.76 Million	-17,650 Reduced 3.09%	554,264 $46.7 Million
Q1 2018 May 15, 2018	BUY	$59.83 - $86.53 $25.9 Million - $37.5 Million	433,546 Added 313.33%	571,914 $46.8 Million
Q3 2017 Nov 14, 2017	BUY	$54.89 - $67.12 $7.6 Million - $9.29 Million	138,368	138,368 $9.24 Million

Others Institutions Holding AGIO

# of Institutions

237

Shares Held

57.1M

Call Options Held

374K

Put Options Held

394K

View Full List

About AGIOS PHARMACEUTICALS, INC.

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $1.83B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

More about AGIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrow Mark Colorado Holdings LLC, based on Form 13F filings with the SEC.

News

Stay updated on Arrow Mark Colorado Holdings LLC with notifications on news.

Account

Arrow Mark Colorado Holdings LLC Agios Pharmaceuticals, Inc. Transaction History